SEINE BIO · SCIENCE LIBRARY

IGF-1 LR3

IGF-1 LR3 is a modified insulin-like growth factor analogue with altered binding-protein interactions.

Research compound

A closer look at the research, the uncertainties and the questions worth asking.

THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026

Inside the science of IGF-1 LR3.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.

Overview

IGF-1 LR3 is a modified insulin-like growth factor analog studied to alter interactions with binding proteins. It is different from ordinary IGF-1 and from the approved medicine mecasermin. A name containing “IGF-1” does not establish that the product shares mecasermin’s clinical evidence, indication, or safety profile.

Community Use

PeptideDosages.com publishes community protocol material for LR3. Performance interest commonly emphasizes growth-factor potency and persistence. These ideas need direct evidence for the actual analog and population; they cannot turn animal pharmacology into a validated muscle-building or recovery regimen.

Doses, Durations & Cycles

Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.

Protocol reference — IGF-1 LR3
Route / formulation	Dose / reported phases	Frequency	Duration / break	Notes and source
Subcutaneous	Weeks 1–2: 20 mcg; weeks 3–4: 40 mcg; weeks 5–8: 50 mcg	Once daily	8 weeks Break: 4–8 weeks	Published informal biohacking claim PepGuru
Standard: subcutaneous or intramuscular; higher-range row: subcutaneous	Standard row: 20–50 mcg; separate higher-range row: 50–100 mcg	Standard: daily or post-workout; higher-range row: daily	4–6 weeks Break: 4 weeks	Published informal biohacking claim Cinch Bio

Important context: LR3 is a modified IGF-1 analog. Native recombinant IGF-1/mecasermin dosing cannot be transferred to LR3. Two webpages document informal schedules; they do not establish a common starting/average/maximum table.

Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.

No FDA-approved LR3 wellness or performance regimen is established. Rat exposures and packaging amounts cannot be scaled into a consumer dose. The chart preserves source context, not directions. Mecasermin’s pediatric label must not be used to calculate an LR3 schedule or to imply that this analog is an approved prescription substitute.

Research Findings

The 1993 comparison examined cell systems and normal female rats. LR3 had reduced affinity for IGF binding proteins and greater growth-related activity in that model, but it also cleared more quickly from rat plasma. That directly cautions against treating a universal multi-day half-life claim as established human pharmacokinetics.

U.S. Approval & Access

IGF-1 LR3 is not FDA-approved. Mecasermin’s approval applies to a different molecule and a defined pediatric condition, not LR3 performance use. A research-only listing does not establish lawful patient availability. The actual compound, preparation, indication, and proposed clinical pathway require independent review.

What It Does in the Body

Modifying binding-protein interactions can change how a growth factor is distributed and how it reaches receptors. More activity in a model does not automatically mean longer persistence or better clinical outcomes. The rat clearance result cannot define reliable human onset, peak exposure, or duration; a wellness result timeline is not established.

Benefits & Reported Experiences

The cited paper did not measure strength, return from injury, or healthy-person body composition in a human trial. Greater potency in rats is not a dependable estimate of a person’s benefit. Clinical claims require the exact analog, a relevant population, meaningful outcomes, and adequate safety follow-up.

Side Effects & Risks

The source set does not provide reliable human adverse-event frequencies for informal LR3 use. IGF-related metabolic and growth activity raises safety questions but does not justify inventing rates for this analog. A clinician should review metabolic history, growth-related conditions, and other hormone exposure rather than borrowing reassurance from a different product.

Delivery Options

Animal and cell experiments do not validate consumer injection routes or local-use claims. Administration near a muscle does not establish selective growth of that muscle. This profile supplies no mixing, injection, dose-conversion, or performance-use instructions and does not endorse research-only materials for personal administration.

Product Quality & Storage

Confirm the precise analog, sequence, and final formulation before comparing a product with the paper. LR3 and mecasermin are not interchangeable quality or evidence categories. A purity certificate cannot establish clinical effectiveness, quantify human risk, or create a lawful clinical pathway for an experimental product. Storage must follow the authorized finished product’s labeling or an approved study protocol; temperatures and beyond-use times cannot be inferred from research-vial guidance.

Combinations & Interactions

Combining LR3 with growth hormone, insulin, or other performance compounds creates additional biological and evidence uncertainty. A paper about one analog in rats cannot establish a safe multi-hormone regimen. This page supplies no stack, cycle, or timing instructions and does not suggest that additional compounds offset risk.

Talking With Your Provider

For fatigue, body-composition concerns, or suspected hormonal problems, begin with a diagnostic clinical review. Discuss established treatments for the actual condition and ask where experimental evidence stops. A consultation can explain LR3 research but does not guarantee access to the analog or enhanced performance.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.

Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.

Questions worth bringing to your appointment.

Are there alternatives that address my goal?
If treatment is appropriate, what monitoring and follow-up would I need?
Could my health history or current medicines change the risks?

Saved discussion topics 0

Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.

Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.

Explore your next step with SEINE BIO.

Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.

Explore consultations Back to Growth-hormone signaling

Educational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.

Bring your saved topics to your care team.

Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.

Choose saved topics for review →